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ABSTRACT
Introduction The number of individuals with gender dysphoria 
seeking gender- affirming treatment is increasing. The short- 
term and long- term effects of masculinising treatment with 
testosterone are debated as serum testosterone increases 
up to 20- fold compared with cisgender women. We will 
investigate short- term and long- term effects of masculinising 
testosterone treatment on preclinical and clinical coronary 
disease, muscle strength and power, oxygen consumption 
(VO2) max, cardiac and respiratory function and quality of life 
including aggression in transgender men.
Methods and analyses Prospective, single- centre, 
observational cohort study at the Body Identity Clinic (BIC), 
Odense University Hospital, Denmark. Investigations are 
performed at inclusion and following 1, 3, 5 and 10 years of 
testosterone therapy. Non- calcified coronary plaque volume 
and calcium score are estimated by coronary CT angiography. 
CT is only performed at inclusion and following 1 and 10 
years. Upper body muscle strength and power are measured 
by a ‘low row’ weight stack resisted exercise machine. 
Evaluation of aggression and quality of life is assessed by 
questionnaires, VO2 max is estimated by maximal testing on 
bike ergometer, and cardiac and respiratory functions are 
measured by echocardiography and spirometry, respectively. 
Markers of cardiovascular risk and inflammation and also 
cortisol and cortisone are assessed in blood, diurnal urine and/
or hair samples. Our cohort (BIC), including dropouts, will be 
an embedded subcohort in a future national registry study in 
all individuals with gender dysphoria and controls. Data are 
available on International Statistical Classification of Diseases 
and Related Health Problems 10th version diagnostic codes, 
prescriptions, socioeconomics and causes of death.
Ethics and dissemination The Regional Committee on Health 
Research Ethics for Southern Denmark (S-20190108) and the 
Danish Data Protection Agency (19/27572) approved the study. 
Signed informed consent will be obtained from all participants. 
All findings will be published in peer- reviewed journals or at 
scientific conferences.
Trial registration number NCT04254354.
INTRODUCTION
Recent European studies report that 0.6%–
0.8% of individuals assigned female at birth 
have incongruent gender identity or gender 
dysphoria.1 2 Testosterone treatment is the 
Strengths and limitations of this study
 ► Body Identity Clinic is a research clinic where this 
prospective longitudinal 10- year cohort study in 
transgender men will assess preclinical coronary 
disease by estimating non- calcified plaque volume 
and calcium score using coronary CT angiography.
 ► The applied methods ensure important health- 
related and sport- related data on upper body muscle 
strength and power, aggression, oxygen consump-
tion max, cardiac and respiratory function in trans-
gender men, during short- term and long- term 
testosterone treatment.
 ► A proper control group is missing, but it is unethical 
to perform a placebo- controlled randomised trial on 
long- term testosterone therapy in persons with gen-
der dysphoria.
 ► Results will only be available in transgender and 
non- binary individuals, treated with testosterone, 
however, a parallel study in transgender women 
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cornerstone of masculinising treatment and is initiated 
in transgender men and by request in non- binary indi-
viduals. Testosterone is an important androgenic and 
anabolic hormone. The androgen effects of testosterone 
include terminal hair growth and deepening of the voice, 
whereas the anabolic effects include muscle growth. Body 
shape changes from feminine to masculine during testos-
terone treatment, as subcutaneous fat is reduced3 and 
redistributed.4 5 The changes in sex hormones are quite 
dramatic in transgender men, as circulating testosterone 
concentrations increase up to 20- fold into the normal 
range for cisgender men,6 while estradiol levels are partly 
supressed.
Clinical coronary disease is rare in young persons,7 
however, preclinical coronary disease is observed and 
testosterone treatment may accelerate non- calcified coro-
nary plaque (NCP) formation. Both NCP and calcified 
plaques may be detected by the sensitive coronary CT 
angiography (CCTA)8 in combination with a semiauto-
mated computer program.9 In a large cardiac CT registry 
study in younger (mean age 39 years) participants, 22% 
of cisgender men and 15% of cisgender women without 
cardiovascular symptoms, had coronary artery disease 
defined as any plaque formation (non- calcified or 
calcified).8 The association between testosterone treat-
ment and NCP formation has been reported in ageing 
cisgender men after 1 year of testosterone treatment,10 
with increased waist to hip ratio at baseline as the stron-
gest predictor of NCP formation.11 There is a lack of 
knowledge regarding NCP formation in relatively young 
transgender men on masculinising testosterone therapy. 
We know that lipid status is deteriorated during masculi-
nising testosterone treatment in transgender men, with 
an increase in low- density lipoprotein (LDL) cholesterol 
and a decrease in high- density lipoprotein (HDL) choles-
terol12 and blood pressure may increase.13 14 However, 
studies on cardiovascular endpoints in transgender men 
are limited and conflicting. A fourfold increased OR for 
myocardial infarction in transgender men was reported, 
which was significant after adjusting for age, diabetes 
mellitus, hypertension, hypercholesterolaemia, chronic 
kidney disease, smoking and exercise levels.15 The study 
design was, however, cross- sectional, hence it was not 
possible to conclude on cause and effect. A retrospective 
study in transgender men reported no cases of myocar-
dial infarction after 10 years of testosterone treatment,16 
but the retrospective study design increased risk of selec-
tion bias due to lost to follow- up before 10 years.
Testosterone treatment is associated with dose- 
dependent increases in muscle mass17 18 and muscle 
strength5 17 in cisgender men. Muscle mass also increases 
during masculinising treatment with testosterone in trans-
gender men,19 but there are limited data on changes in 
muscle strength before and during masculinising testos-
terone treatment. One study reported higher lower body 
muscle strength during gender affirming treatment with 
testosterone.20 Upper body muscles have higher number 
of androgen receptors than lower body muscles21 and 
characterising muscle strength and power in the large 
muscles of the arms and upper back during testosterone 
treatment in transgender men would be of interest. 
Grip strength was higher in transgender men compared 
with cisgender women.22 However, the study was cross- 
sectional, and hand grip strength only tests the small 
muscles of the hand and lower arm.
The World Professional Association for Transgender 
Health (WPATH)23 recommends to warn against elevated 
aggression levels as a psychological adverse effect of 
masculinising testosterone treatment in transgender 
men, however, this presumption was not supported by 
recent data.24 25 The term aggression covers a wide range 
of intercorrelated behaviours, thoughts and emotions. 
There is no uniform definition of aggression26 and 
studies reporting increased aggression scores during 
testosterone treatment27 had severe methodological 
problems and high risk of bias. Valid information on 
aggression constructs27 during short- term and long- term 
testosterone therapy is ensured in the present study by 
a questionnaire, which incorporates all dimensions of 
aggression28 and questionnaires containing information 
on anxiety, depression, testosterone dose, duration of 
treatment and physical health.
Low cardiorespiratory fitness has been associated with 
an increased risk of premature death from all causes, 
but cardiovascular disease is the most common cause of 
death in cisgender individuals.29 The maximum oxygen 
consumption (VO2 max), determined from a graded 
maximal exercise test, is an approved way of classifying 
cardiorespiratory fitness levels.30 VO2 max is gener-
ally higher in cisgender men compared with cisgender 
women,31 presumably due to differences in muscle mass, 
cardiac output, haematocrit and lung size. There are no 
prospective data on VO2 max during masculinising testos-
terone treatment in transgender men, but VO2 max is 
expected to increase, as testosterone increased muscle 
mass20 and haematocrit.14 Exogenous testosterone 
increased aerobic running time in young physically active 
cisgender women32; testosterone gel, 10 mg per day for 
10 weeks, was used, the dose equals 20% of masculinising 
testosterone treatment.
Obstructive and restrictive estimates of respiratory func-
tion are estimated by spirometry and reference ranges for 
spirometry vary with gender assigned at birth, weight, 
height and age. Asthma is characterised by obstruc-
tively decreased respiratory function with airway hyper- 
responsiveness and inflammation. Asthma is much more 
prevalent in cisgender women compared with cisgender 
men33; however, we have no reference ranges for respira-
tory function in transgender men.34
Masculinising testosterone treatment in transgender 
men is for life and currently no prospective data are 
available on long- term morbidity. This study will provide 
important information on health issues regarding cardio-
vascular and respiratory health and upper body muscle 
strength and power. Aggression levels may be elevated 
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has not been clarified. The combination of long- term 
clinical observational data and access to national registry 
data will provide further knowledge on benefits and risks 
of masculinising testosterone treatment.
Aim
To investigate short- term and long- term effects of mascu-
linising testosterone treatment on preclinical and clin-
ical coronary disease, muscle strength and power, VO2 
max, cardiac and respiratory function and quality of life 
including aggression in transgender men.
We hypothesise that, in transgender men:
Masculinising testosterone treatment accelerates NCP 
development and progression.
Testosterone treatment will be associated with long- 
term increase in upper body muscle strength and power, 
VO2 max, cardiac and respiratory function.
Aggression scores will increase during initiation 
of testosterone treatment, but the aggression scores 
will return to baseline during long- term testosterone 
treatment.
METHODS AND ANALYSIS
Study population and recruitment
Participants are individuals assigned female at birth 
with a diagnosis of gender dysphoria treated with testos-
terone or approved to start treatment with testosterone. 
Only individuals associated with one of the three centres 
of gender identity in Denmark: Odense, Aalborg and 
Copenhagen are included. No individual with known use 
of ‘self- prescribed’ sex hormones is included. The inclu-
sion period for the cohort (N=200) is estimated to last 2 
years.
Study design
For study outline, please see figure 1. The study is a 
prospective single- centre observational cohort study at 
Body Identity Clinic (BIC), Odense University Hospital, 
Odense, Denmark of 10 years duration. Participants 
(aged 18 years and older) are invited for five visits (base-
line, 1, 3, 5 and 10 years) after informed consent has 
been given. The participants will spend 1 day in BIC per 
visit and all examinations use the same equipment and 
study protocols (table 1). Ethical permission has been 
obtained for the use of registry data regarding Interna-
tional Statistical Classification of Diseases and Related 
Health Problems 10th version (ICD-10) diagnostic codes, 
medical treatment, socioeconomics and causes of death 
in all participants including participants lost to follow- up. 
The participants accept study participation by written 
informed consent. All individuals in Denmark have a 
civil registration number (CPR) reflecting binary gender. 
During legal transitioning individuals may change CPR 
and data from the two CPR numbers is merged. We will 
be able to compare study participants with participants 
lost to follow- up by combining the clinical outcomes with 
registry data (table 1, figure 1).
Patient and public involvement statement
An advisory board of transgender men has been estab-
lished. The participant advisory board meetings were 
Figure 1 Study outline.
Table 1 Overview of study outcomes and visits
Investigations Inclusion 1 year 3 years 5 years 10 years
Coronary CT angiography X X     X
Muscle strength and power X X X X X
Aggression and quality of life questionnaires X X X X X
VO2 max X X X X X
Echocardiography X X X X X
Spirometry X X X X X
Blood, urine and hair samples X X X X X
DXA whole- body and bone density X X X X X
Medical history X X X X X
Physical examination X X X X X
DXA, Dual x- ray absorptiometry; VO2 max 
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arranged prior to application for ethical approval of the 
study to secure inputs in terms of relevance of research 
questions, recruitment, outcomes and participant 
time consumption. The participant advisory board has 
read and commented on the study material and will be 






Upper body muscle strength and power.
Aggression and quality of life.
VO2 max.
Left ventricular muscle mass and function.
Respiratory function.
Serum levels of testosterone, estradiol and cortisol.
Circulating markers of cardiovascular risk and 
inflammation.
Diurnal urine and hair samples for assessment of cortisol 
and cortisone.
Outcomes
Outcomes and visits are outlined in table 1.
Coronary CT angiography
CCTA (high- end CT scanner) is conducted at the first 
visit, after 1 year and at 10- year follow- up (table 1) to 
examine the presence of NCP and calcified coronary 
plaques (figure 2). The scanning protocol depends on 
the patient heart rate. In patients with a stable heart 
rate above 60 beats per minute, orally or intravenously 
β-blocker are administered until the heart rate is appro-
priate (if possible below 60), and a prospectively gated 
protocol is used. Participants with a heart rate >70 bpm 
despite β-blocker pretreatment are subjected to a retro-
spectively gated scan with dose modulation. Addition-
ally, sublingual nitrates are administered prior to the 
scan. Administrating of β-blocker and nitrates are in 
accordance to daily clinical practice. An experienced 
cardiologist performs data analyses of NCPs, calcium 
score/stenosis and pericardial fat using a semiautomatic 
program.9 Radiation amounts to 1.6 mSv per CCTA. We 
have ethical permission to perform three CCTAs during 
the study period of 10 years. Radiation from CCTA is 
lower than expected and we are applying for an addi-
tional CCTA at 5 years.
Upper body muscle strength and power
A ‘low row’ weight stack resisted exercise machine (Tech-
nogym, Italy) tests arm and upper back muscles. The 
machine is adjusted to fit the individual participant rela-
tive to body height and arm length. Body weight, training 
history and age estimates initial loading. Warm- up is 
3×10 and 1×5 repetitions at the estimated test load, with 
1 min of rest in between sets. Subsequently maximal 
effort (one repetitions maximum, 1RM) is obtained using 
single repetitions with increasing load until task failure 
(the participant is unable to complete the full range of 
motion) with 2 min of rest in between sets. Hereafter 
participants are instructed to perform at least 3 sets of 
one repetition as forceful and fast as possible to evaluate 
muscle power with a load corresponding to 80% of 1RM 
and 2 min of rest in between sets. During each repetition, 
peak and mean power is measured. To evaluate muscle 
power we attach a PUSH V.2.0 inertial motion device 
(PUSH, Toronto, Canada) to the weight stack. The PUSH 
device includes a three- axis accelerometer and gyroscope, 
enabling measurements of human movement kinematics 
at a sampling rate of 1000 Hz. Previously, PUSH has been 
validated to evaluate power using resistance exercises.35 
Peak and mean power (watt), respectively, are calculated 
based on kinematic data derived by the PUSH software.
Questionnaires
Buss- Perry Aggression Questionnaire, Quality of life: 
SF-36, Inventory of Interpersonal Problems, Gender Q 
(Development in progress), General Anxiety Disorder-7 
and Patient Health Questionnaire-8.
Vo2 max
Measurement of VO2 max is performed on a bike ergom-
eter and Vyntus CPS system. The resistance will start 
low and increase gradually until maximum capacity or 
exhaustion. At maximum capacity lactate is measured.
Echocardiography
A comprehensive transthoracic echocardiography is 
performed by a medical doctor. The recordings are stored 
digitally for blinded analysis. The followings are included: 
Size and mass of all cardiac chambers, left ventricle ejec-
tion fraction, global longitudinal strain, left ventricle 
diastolic function and heart valve function.
Respiratory function
Respiratory function is tested by a spirometer (Vyntus 
CPS system) measuring forced expiratory volume in 1 s, 
forced vital capacity and peak flow.
Blood, urine and hair samples
Testosterone, estradiol and cortisol levels and cardio-
vascular risk markers in blood and serum (HbA1c, 
lipids, haematocrit, adiponectin, soluble urokinase- type 
Figure 2 The figure displays a coronary CT angiography. A 
semiautomatic programme detects non- calcified coronary 
plaque. LAD,left anterior descending artery; LCX, left 
circumflex artery; LMCA, left maincoronary artery; OM, 
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plasminogen activator receptor (suPAR)) are analysed 
along with inflammation markers in blood and serum (C 
reactive protein (CRP), interleukin 6 (IL-6)). Hormone 
levels are measured after an overnight fast between 
8:00 and 9:00 hours by liquid chromatography tandem 
mass spectrometry (LC- MS/MS), which is calibrated 
by in- house prepared calibrators, and the relative SD is 
<10%. Quality for steroid hormones is assured by monthly 
participation in the external quality control programme 
for steroid hormones from The UK National External 
Quality Assessment Service (UK NEQAS). Sex hormone 
binding globulin is determined on serum samples by 
a Roche assay on Cobas e602 with a precision of 1.8 
%−4.0% (14.9–21.9 nmol/L). Free testosterone levels are 
calculated assuming a plasma albumin concentration of 
43 g/L.36
Haemoglobin is measured using a photometric analyser 
with a coefficient of variation (CV) of 2.8%. Plasma total 
cholesterol and HDL cholesterol are analysed by enzy-
matic colorimetric reactions (Modular P, Roche), and 
LDL cholesterol is calculated using the Friedewald equa-
tion.37 HbA1c is measured by high- performance liquid 
chromatography using Tosoh G8 (Medinor, Broendby, 
Denmark); the analytical CV is 0.9%. Adiponectin is 
determined by an in- house time resolved immunofluo-
rometric assay,38 with intra- assay and interassay CV aver-
aging 5% and 10%, respectively.
Plasma suPAR is measured with the suPARnostic ELISA 
(ViroGates A/S, Birkerød, Denmark) with a mean CV 
of 4%. CRP is analysed using latex based immunoanal-
ysis (CRP Ultra, Sentinel Diagnostics, Milan, Italy) by 
an Architect c8000 instrument (Abbott). The intra- assay 
and interassay CVs are 0.8% and 1.9% for normal levels 
of CRP, respectively. Plasma IL-6 is measured with Quan-
tikine HS- IL-6 ELISA (R&D Systems, Minneapolis, USA) 
with a mean CV of 8%.
Diurnal urine samples: Participants are instructed 
to note the time for voiding in the morning before 
starting sample collection, and all urine collected until 
the morning of the second day. Urine samples are kept 
frozen at −20°C until analysis. Cortisol and cortisone 
are analysed by LC- MS/MS. Urine samples are solid 
phase extracted on an Oasis HLB 96- well plate after 
addition of deuterated internal standards; the anal-
ysis is calibrated by in- house prepared calibrators, and 
the relative SD is <10%. Quality is assured by monthly 
participation with satisfactory results in the external 
quality control programme for steroid hormones from 
the UK NEQAS.
Hair samples: A section of hair strands approximately 
3 mm in diameter is cut as close to the scalp as possible 
from the posterior vertex area. Hair samples are stored 
in aluminium foil as previously described,39 the 4 cm 
hair segment closest to the scalp is used for analyses to 
represent cortisol secretion over the most recent 4- month 
period.40 The analyses will be carried out at Department 
of Psychology, Technical University of Dresden, Germany 
using LC- MS/MS.41
Whole-body dual X-ray absorptiometry and bone mineral 
density
Dual X- ray absorptiometry, Horizon A Discovery is used 
to measure whole- body lean body mass, fat mass and bone 
density. Radiation amounts to 0.1 mSv per scan.
Medical history
Chronic diseases, medication and supplements, alcohol, 
tobacco and abuse, gynaecological history, previous treat-
ment with testosterone, information on diet and physical 
activity are recorded.
Physical examination
Height, weight, body mass index (BMI, kg/m2), blood 
pressure, waist and hip circumference and face and body 
hair (Ferriman- Gallwey Score) are recorded.
Sample size and statistics
The primary study endpoint is NCP. We have estimated 
the sample size, as no valid data exist for a proper power 
calculation regarding the primary endpoint, NCP. We 
aim to include 200 participants, including 50 men who 
are approved to start testosterone treatment based on the 
power calculation of the main secondary endpoint, upper 
body muscle strength and power. Sample size estimation 
for upper extremity muscle strength and power was based 
on data (mean baseline/SD) from a comparable cohort.42 
The estimation was based on a 10% within- participant 
difference (deemed as functional relevant) with an alpha 
level of 0.05 and a statistical power of 0.80. On the basis 
of this data, a sample size of 39 was sufficient to detect 
within- participants differences with two- tailed compar-
ison. To account for potential drop- outs (estimated to 
20%) 50 individuals approved to start testosterone treat-
ment will be recruited for the trial.
Normally and non- normally distributed data will be 
analysed using parametric and non- parametric statis-
tics, respectively. Associations between testosterone and 
endpoints will be investigated with multiple linear regres-
sion modelling. Random mixed- effects linear regres-
sion models will be applied to investigate associations 
between testosterone and longitudinal repeated markers 
of assessed outcomes. We will collaborate with a statisti-
cian regarding random mixed- effects linear regression 
modelling.
A directed acyclic graph will be depicted in order to 
transparently identify a priori assumptions of causal rela-
tions between exposure, outcome, potential confounders, 
intermediate factors and selection bias. Missing data will 
be handled according to type. Depending on data, anal-
yses will be performed based on either complete case 
analyses or, if appropriate, by imputing missing data in 
collaboration with the statistical department. Analyses 
will be conducted using STATA V.14 (StataCorp 2015). 
Post regression diagnostics/model validation will be 
performed. Assumptions of linearity between predic-
tors and the outcome variable will be inspected by using 
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plots. Normality of predicted residuals will be checked 
with quantile- normal and probability- normal plots. 
Homogeneity of variance (homoscedasticity) of the resid-
uals will be investigated by plotting residuals against the 
fitted (predicted) values. Multicollinearity will be assessed 
using variance inflation factors. Open- ended questions 
will not be included. Data are anonymised according to 
Danish law and regulations (The Regional Committees 
on Health Research Ethics for Southern Denmark, Proj-
ect- ID: S-20190108, The Danish Data Protection Agency, 
journal no. 19/27572), and therefore analyses will be 
performed through a remote VPN access to Statistics 
Denmark.
Data management
Data are stored and analysed electronically and unau-
thorised access denied. Original data are filed according 
to one participant number. Research Electronic Data 
Capture (REDCap) ( www. project- redcap. org), hosted by 
Open Patient data Explorative Network (OPEN), is used 
for registration of data.43 44 REDCap meets the safety 
requirements set by the Danish Data Protection Agency 
for storage of person- sensible data. OPEN Analyse, a 
secure remote desktop solution hosted by OPEN, is used 
for storage and analyses of the pseudoanonymised data.
ETHICS AND DISSEMINATION
All participants give written informed consent. The study 
results will be published in peer- reviewed journals, publi-
cation will be according to the International Committee of 
Medical Journal Editors recommendations and the inves-
tigators oblige themselves to publish both positive and 
negative findings. The study is performed in accordance 
with theDeclaration of Helsinki and regulations of the 
General Data Protection Regulation. It is approved by the 
Danish Data Protection Agency (journal no. 19/27572), 
the Regional Committees on Health Research Ethics for 
Southern Denmark (project- ID: S-20190108).
DISCUSSION
Preclinical coronary disease is determined by NCP volume 
and calcium score in transgender men during this 10- year 
prospective cohort study at BIC. NCP volume is assessed 
by state- of- the- art CCTA and we use the lowest detectable 
change in NCP formation (1 mm3) as the clinically rele-
vant difference.45 However, a proper power calculation 
regarding our primary endpoint cannot be performed as 
no previous data has been published. Therefore, distribu-
tion of data is unknown and the SD cannot be calculated. 
The possible lack of NCP development during 10 years 
is acknowledged, but this potential negative result would 
be reassuring and clinical relevant. In a large cardiac CT 
registry study in relatively young cisgender men (mean 
age 39±6 years), 424 out of 1143 participants did not have 
any cardiovascular symptoms.8 Experienced cardiolo-
gists assessed the CCTAs, reporting coronary plaque of 
any kind in 22% of asymptomatic 424 cisgender men.8 In 
our study, we increase the sensitivity of detecting NCPs by 
using a semiautomatic programme, which is comparable 
to Autoplaque.9
We also aim at providing new scientific evidence 
regarding upper body muscle strength and power in men 
on masculinising therapy. Upper body muscles are of 
special interest as the number of androgen receptors are 
higher in the upper body muscles compared with lower 
body.21 Also, our study will elaborate on interesting data 
on possible increased levels of aggression during testos-
terone therapy and the temporal relation between mascu-
linising testosterone treatment and levels of aggression.27 
Aggression is very relevant clinical issue in the context 
of the WPATH warning regarding aggression on testos-
terone therapy.23 We will report new data on VO2 max and 
cardiac function as improvements in cardiorespiratory 
fitness are associated with considerably reduced mortality 
risk and adverse cardiovascular event rates29; furthermore, 
data on respiratory function will add new knowledge and 
all the above- mentioned results are important for trans-
gender men and non- binary individuals on testosterone 
therapy in health and sports.
Ethical permission is granted to access registry data 
from all participants including those, who leaves the 
clinical study part. Registry data will provide knowledge, 
regarding national ICD-10 diagnostic codes, medical treat-
ment, socioeconomics and causes of death. Future access 
to national registry data in all individuals with registered 
gender dysphoria and controls will allow us to study our 
cohort (BIC) as an embedded subcohort including indi-
viduals, who remain in the 10- year study as well as drop-
outs. We have previously used this design in women with 
polycystic ovary syndrome.46 The gold- standard research 
design to assess benefits and risks of testosterone therapy 
in transgender persons is a long- term placebo- controlled 
randomised trial on masculinising therapy, however, it is 
deeply unethical to perform such a study, when gender 
dysphoria is present. Apart from the future registry study 
we will compare data from our cohort to results from 
Odense Androgen Study (OAS).6 47–49 OAS is a large 
cross- sectional study in 783 young healthy men (20–29 
years old); data are available on BMI, waist circumfer-
ence, muscle mass, fat mass, blood pressure, Hba1c, 
testosterone and estradiol levels, lipid status and VO2 max 
and a follow- up is planned (Ethical Committee Journal 
number, S-20130097). Our study is a non- representative 
cohort study with risk of selection bias regarding age, 
BMI, smoking, ethnicity, fitness level and morbidity. Data 
on health consequences regarding all aspects of gender 
affirming treatment is warranted, however, this study will 
only provide information on transgender men and non- 
binary persons on testosterone therapy. To counteract 
this unbalance, a parallel study has been planned in trans-
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